Kamela Bellovoda
A5060324988- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- RNA and protein synthesis mechanisms
- Advanced biosensing and bioanalysis techniques
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- Extracellular vesicles in disease
- Viral Infections and Vectors
- Virus-based gene therapy research
- Click Chemistry and Applications
- Computational Drug Discovery Methods
- interferon and immune responses
- Protein Structure and Dynamics
- Nanoparticle-Based Drug Delivery
Mersana Therapeutics (United States)
2023
Sarepta Therapeutics (United States)
2020-2021
Massachusetts General Hospital
2020
Antibody-drug conjugates (ADC) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many types. The activity safety profile of an ADC depends on its construction: antibody, payload, linker, conjugation method, as well the number payload drugs per antibody [drug-to-antibody ratio (DAR)]. To allow for optimization given target antigen, we developed Dolasynthen (DS), novel platform based auristatin hydroxypropylamide, that enables precise DAR-ranging site-specific...
Therapeutic macromolecules such as proteins and oligonucleotides can be highly efficacious but are often limited to extracellular targets due the cell's impermeable membrane. Cell-penetrating peptides (CPPs) able deliver into cells, structure-activity relationships inconsistent literature reports make it difficult design effective CPPs for a given cargo. For example, polyarginine motifs common in CPPs, promoting cell uptake at expense of systemic toxicity. Machine learning may address this...
Abstract There are more amino acid permutations within a 40-residue sequence than atoms on Earth. This vast chemical search space hinders the use of human learning to design functional polymers. Here we couple supervised and unsupervised deep with high-throughput experimentation drive high-activity, novel sequences reaching 10 kDa that deliver antisense oligonucleotides nucleus cells. The models, in which natural unnatural residues represented as topological fingerprints, decipher visualize...
<p>Supplementary Materials</p>
<div>Abstract<p>Antibody-drug conjugates (ADCs) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many types. The activity safety profile of an ADC depends on its construction: antibody, payload, linker, conjugation method, as well the number payload drugs per antibody (drug-to-antibody ratio, DAR). To allow for optimization given target antigen, we developed Dolasynthen, novel platform based auristatin hydroxypropylamide (AF-HPA), that enables...
<p>Supplementary Materials</p>
<div>Abstract<p>Antibody-drug conjugates (ADCs) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many types. The activity safety profile of an ADC depends on its construction: antibody, payload, linker, conjugation method, as well the number payload drugs per antibody (drug-to-antibody ratio, DAR). To allow for optimization given target antigen, we developed Dolasynthen, novel platform based auristatin hydroxypropylamide (AF-HPA), that enables...
<p>Supplementary Materials</p>
<p>Supplementary Materials</p>
<div>Abstract<p>Antibody–drug conjugates (ADC) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many types. The activity safety profile of an ADC depends on its construction: antibody, payload, linker, conjugation method, as well the number payload drugs per antibody [drug-to-antibody ratio (DAR)]. To allow for optimization given target antigen, we developed Dolasynthen (DS), novel platform based auristatin hydroxypropylamide, that enables...